The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. This is an opportunity for a Medical Director who enjoys being close to the science and the study: translating emerging biology into thoughtful clinical research strategies, designing studies that answer important development questions, and working side-by-side with colleagues across Research, Clinical Operations, Regulatory, Biostatistics, Clinical Pharmacology, Drug Safety, and other disciplines.